Biotech · Private company
argenx
Track this companyFree. Adds argenx to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs26From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline26
- Efgartigimod IVPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod IV or Efgartigimod PH20 SCPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- efgartigimod PH20 SCPhase 3 · Primary Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SCPhase 3 · Graves' DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SCPhase 3 · MyositisClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SCPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- empasiprubartPhase 3 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- EmpasiprubartPhase 3 · Multifocal Motor Neuropathy (MMN)ClinicalTrials.gov · fetched Nov 12, 2026
- Empasiprubart IVPhase 3 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- IVIgPhase 3 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- IVIG (Intravenous Immunoglobulin)Phase 3 · Multifocal Motor Neuropathy (MMN)ClinicalTrials.gov · fetched Nov 12, 2026
- ARGX-117Phase 2 · Delayed Graft FunctionClinicalTrials.gov · fetched Nov 12, 2026
- ARGX-119 IVPhase 2 · Spinal Muscular Atrophy (SMA)ClinicalTrials.gov · fetched Nov 12, 2026
- ARGX-121Phase 2 · Immunoglobulin A Nephropathy (IgAN)ClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod IVPhase 2 · AChR-Ab Seropositive Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 (ARGX-113) SCPhase 2 · Autoimmune Encephalitis (AE)ClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SCPhase 2 · Systemic Sclerosis (SSc)ClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SCPhase 2 · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)ClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SC PFSPhase 2 · AChR-Ab Seropositive Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Empasiprubart IVPhase 2 · AChR-Ab Seropositive Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Empasiprubart IVPhase 2 · DermatomyositisClinicalTrials.gov · fetched Nov 12, 2026
- ARGX-119Phase 1 · Congenital Myasthenic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod IVMyasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SCChronic Inflammatory Demyelinating PolyradiculoneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- Efgartigimod PH20 SC PFSMyasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Empasiprubart IVMyasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsPHASE2 · NOT_YET_RECRUITING · started Apr 1, 2027ClinicalTrials.gov NCT07583641 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANPHASE2 · RECRUITING · started Nov 5, 2026ClinicalTrials.gov NCT07773727 · fetched Nov 12, 2026
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisPHASE2 · RECRUITING · started Jul 10, 2026ClinicalTrials.gov NCT07673627 · fetched Nov 12, 2026
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseasePHASE3 · RECRUITING · started Jun 10, 2026ClinicalTrials.gov NCT07570316 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular AtrophyPHASE2 · RECRUITING · started Dec 19, 2025ClinicalTrials.gov NCT07287982 · fetched Nov 12, 2026
- ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodPHASE2 · RECRUITING · started Dec 19, 2025ClinicalTrials.gov NCT07284420 · fetched Nov 12, 2026
- ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia GravisRECRUITING · started Dec 19, 2025ClinicalTrials.gov NCT07294170 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPPHASE3 · RECRUITING · started Sep 16, 2025ClinicalTrials.gov NCT07091630 · fetched Nov 12, 2026
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPHASE3 · RECRUITING · started Aug 22, 2025ClinicalTrials.gov NCT06920004 · fetched Nov 12, 2026
- Efgartigimod for the Treatment of Acute Optic NeuritisPHASE2 · RECRUITING · started Aug 12, 2025ClinicalTrials.gov NCT06453694 · fetched Nov 12, 2026
- Real-World Efgartigimod Effectiveness in CIDP: A Prospective StudyRECRUITING · started Aug 11, 2025ClinicalTrials.gov NCT07264426 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 18, 2024ClinicalTrials.gov NCT06742190 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 11, 2024ClinicalTrials.gov NCT06655155 · fetched Nov 12, 2026
- A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)PHASE1 · ACTIVE_NOT_RECRUITING · started Sep 24, 2024ClinicalTrials.gov NCT06436742 · fetched Nov 12, 2026
- A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 20, 2024ClinicalTrials.gov NCT06284954 · fetched Nov 12, 2026
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisPHASE2_PHASE3 · RECRUITING · started Jun 28, 2024ClinicalTrials.gov NCT06392386 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 16, 2024ClinicalTrials.gov NCT06298552 · fetched Nov 12, 2026
- ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft FunctionPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 17, 2024ClinicalTrials.gov NCT05907096 · fetched Nov 12, 2026
- A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4ACTIVE_NOT_RECRUITING · started Feb 13, 2024ClinicalTrials.gov NCT06078553 · fetched Nov 12, 2026
- A Prospective Longitudinal Study in Adults With Multifocal Motor NeuropathyACTIVE_NOT_RECRUITING · started Nov 29, 2023ClinicalTrials.gov NCT05988073 · fetched Nov 12, 2026
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyPHASE3 · ENROLLING_BY_INVITATION · started Sep 12, 2023ClinicalTrials.gov NCT05979441 · fetched Nov 12, 2026
- Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisPHASE2_PHASE3 · ENROLLING_BY_INVITATION · started Aug 18, 2022ClinicalTrials.gov NCT05374590 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 17, 2021ClinicalTrials.gov NCT04812925 · fetched Nov 12, 2026
- Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 26, 2021ClinicalTrials.gov NCT04833894 · fetched Nov 12, 2026
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 18, 2020ClinicalTrials.gov NCT04280718 · fetched Nov 12, 2026